<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Contrast Induced Nephropathy • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Contrast Induced Nephropathy • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/contrast induced nephropathy/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/contrast induced nephropathy/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="contrast-induced-nephropathy" tabindex="-1">contrast induced nephropathy</h1>
<ul>
<li>related: <a href="/wiki/notes/Nephrology/">Nephrology</a></li>
<li>tags: #nephrology</li>
</ul>
<hr>
<p><mark>Contrast-associated nephropathy</mark> (CAN), defined as an <mark>increase in serum creatinine levels within 24 to 48 hours of contrast exposure</mark>, is a common cause of reversible AKI in the hospital setting. Contrast-induced nephropathy (CIN) includes that subset of CAN in which the kidney injury can be more definitively linked to the contrast. Multiple risk factors have been associated with CAN, but a baseline reduction in eGFR appears most important, especially in patients with AKI and in patients with CKD and an eGFR &lt;30 mL/min/1.73 m2.</p>
<p>CIN is thought to be due to ATN from contrast-induced vasoconstriction, decreased renal blood flow, medullary hypoxia, oxidative stress, and direct tubular cytotoxicity. AKI tends to be <mark>nonoliguric</mark>, with an <mark>FENa &lt;1%</mark>. The urinary sediment may be bland or show classic ATN findings.</p>
<p>Preventive strategies for patients at high risk for CIN include minimizing the amount of contrast, using low or iso-osmolar contrast, discontinuing nephrotoxins, and prophylactically administering <mark>intravenous isotonic saline</mark>. Prophylactic saline should be administered to all patients with an eGFR &lt;30 mL/min/1.73 m2 and should be considered for patients with an eGFR of 30 to 44 mL/min/1.73 m2 who have other risk factors for AKI. A randomized controlled trial demonstrated that oral acetylcysteine was no more effective than placebo for the prevention of CIN. Statins have been shown in observational studies and several randomized controlled trials to prevent CIN by acting as stabilizers of the endothelium and free radical scavengers in a model of ischemic nephropathy. Further studies are needed to establish their benefit. There is no role for prophylactic hemodialysis or hemofiltration following contrast exposure. Treatment of CIN is supportive.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Nephrology/" class="peer">Nephrology</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="nephrology" tabindex="-1">Nephrology</h1>
<hr>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2 id="to-learns" tabindex="-1">To learns</h2>
<ul>
<li>ANCA vasculitis</li>
<li>[ ] stones: citrate and calcium physiology</li>
</ul>
<h2 id="mksap" tabindex="-1">MKSAP</h2>
<p>Chapter 01Clinical Evaluation of Kidney Function
Chapter 02Fluids and Electrolytes
Chapter 03Acid-Base Disorders
Chapter 04Hypertension
Chapter 05Chronic Tubulointerstitial Nephritis
Chapter 06Glomerular Diseases</p>
<ul>
<li><a href="/wiki/notes/Kidney%20Manifestations%20of%20Deposition%20Diseases/">Kidney Manifestations of Deposition Diseases</a>
Chapter 08Genetic Disorders and Kidney Disease
Chapter 09Acut</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
